What is Genome Engineering Market?
Genome Engineering enables scientists to make changes to DNA, leading to changes in physical traits, like eye color, and disease risk. These technologies act like scissors, cutting the DNA at a specific spot. Then scientists can remove, add, or replace the DNA where it was cut. Scientists are developing gene therapies - treatments involving genome engineering - to prevent and treat diseases in humans. Genome engineering tools have the potential to help treat diseases with a genomic basis, like cystic fibrosis and diabetes, etc.
The market study is being classified by Type (Reagents & Consumables, Software & Systems and Services), by Application (Cell Line Engineering , Animal Genetic Engineering , Plant Genetic Engineering and Others) and major geographies with country level break-up.
Thermo Fisher Scientific (United States), Merck & Co (Germany), Horizon Discovery Limited (United Kingdom), Genscript USA (United States), Sangamo Therapeutics (United States), Integrated DNA Technologies (United States), Lonza Group (Switzerland), New England Biolabs (United States), Origene Technologies (United States) and Transposagen Biopharmaceuticals (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Cellecta (United States), Genecopoeia (United States) and Calyxt (United States).
The companies operating in this sector are concentrating more on efficient growth, upgrading operational efficiency and productivity, realizing high safety standards, and focus on maintaining sustainable development. The players are focusing on securing the leading position in this industry. They are uninterruptedly observing for the prospect to reinforce their economic advantage. To meet a high market share, and developing socially responsible business companies are identifying various strategic initiatives such as mergers & acquisitions, new product launch, product enhancement, and others. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Genome Engineering market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Genome Engineering market by Type, Application and Region.
On the basis of geography, the market of Genome Engineering has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increasing Development of Novel Technologies in Genome Engineering
- Surging Prevalence of Genetic Disorders
Market Trend
- Rising Governments Fundings for R&D in Genome Engineering
- Increasing Number of Strategic Initiative by Leading Players across the Industry
Restraints
- High Cost of Genome Engineering Technologies
Opportunities
- High Demand for Genome Engineering in Personalized Medicine
- Growth Potential in Emerging market
Challenges
- Complex Technology and Required High Skilled Researchers
Market Leaders and some development strategies
In Nov 2020, Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.
In Feb 2018, Sangamo Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom has granted the Clinical Trial Authorisation (CTA) for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating SB-FIX, a zinc finger nuclease (ZFN)-mediated in vivo genome editing treatment for hemophilia B.
Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Genome Engineering Service Providers, Government Regulatory and Research Organizations and End-Use Industries
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase